A Phase 1b, Multicenter, Open-Label Study of Valemetostat Tosylate in Combination with Deruxtecan Antibody-drug Conjugates in Subjects with Solid Tumors

Protocol No
DAIICHI-DS3201-324
Staff Member
Hui-Zi Chen
Phase
I
Summary

The main purpose of this study is to gather information about the investigational drug (a drug
that is being studied and has not been approved for sale or use in your disease), valemetostat tosylate (Valemetostat) given in combination with DXd ADCs (a type of drug called an antibody drug conjugate) to determine if the drug combination might help to treat several types of solid tumors.

Objective
A Phase 1B Study of Valemetostat in Combination with Deruxtecan in Patients with Solid Tumors
WITH DXd ADCs
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL